Tikvah Management, which owns approximately 1.5% of the outstanding common shares of Quanterix (QTRX) intends to vote against the company’s proposed merger with Akoya Biosciences (AKYA) at the upcoming Quanterix Special Meeting of shareholders. The firm said, “As a significant investor in the company since 2018, Tikvah believes the proposed merger is not in the best interest of Quanterix’s shareholders. Tikvah echoes the public comments made by other investors opposing the merger, including that the proposed transaction undervalues Quanterix’s shares, there would be a significant reduction in the Company’s cash runway post-merger, and that Quanterix’s business is far superior to Akoya’s. Tikvah reserves the right to change this intention should there be significant new developments.”